• AstraZeneca & Chi-Med: Harnessing the potential of Chinese science innovation

    976 views 1 month ago
    In December 2011, AstraZeneca and Chi-Med signed a global licensing, co-development and commercialisation agreement for a novel, potent ATP-competitive c-Met inhibitor for treatment of solid tumours. Six clinical studies are now running across several countries, with clinical activity observed in kidney, lung, stomach and colon cancers. Show less
    Read more
  • Uploads Play

    This item has been hidden
to add this to Watch Later

Add to

Loading playlists...